Verifying…
Home / Drug A–Z / Nidof Tablet_

Nidof Tablet_

NAFDAC Reg. No. A4-8011 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Nidof Tablet_
NAFDAC number
A4-8011
Active ingredient
Ofloxacin; Ornidazole
Strength
200 mg; 500 mg
Form
Tablet
Pack size
10 x 10's, 2 x 7's (in Alu-Alu blisters)
Manufacturer
Not listed
Applicant (holder)
Tamar & Pharez Nig Ltd
Approved
29 Oct 2025
Status
Active View on NAFDAC ↗
Registration valid to
28 Oct 2030
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Nidof Tablet_ is on the NAFDAC register with an active registration (A4-8011). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Nidof Tablet_

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:

How to take it and how often
  • The recommended dosage regimen
  • For the treatment of bacterial conjunctivitis is: Days 1 and 2 Instill one to two drops every two to four hours in the affected eye(s)
  • Days 3 through 7 Instill one to two drops four times daily
  • The recommended dosage regimen
  • For the treatment of bacterial corneal ulcer is: Days 1 and 2 Instill one to two drops into the affected eye every 30 minutes, while awake
  • Awaken at approximately four and six hours after retiring and instill one to two drops
  • Days 3 through 7 to 9 Instill one to two drops hourly, while awake
  • Days 7 to 9 through treatment completion Instill one to two drops, four times daily
Children
  • Safety and effectiveness in
  • Infants below the age of one year have not been established
  • Quinolones, including ofloxacin, have been shown to cause arthropathy in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any arthropathy
  • There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints
Older adults

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

While you are taking it
  • Avoid contaminating the applicator tip with material from the eye, fingers or other source
  • Systemic quinolones, including ofloxacin, have been associated with hypersensitivity reactions, even following a single dose
  • Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction
Talk to a doctor first if

Ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see WARNINGS ).

Medicines it may not mix with

Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

Warnings

NOT FOR INJECTION. Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. …

Possible side effects

Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness and nausea have been received. Refer to WARNINGS for additional adverse reactions. To report SUSPECTED ADVERSE REACTIONS, contact Sentlss at 1--855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy and breastfeeding

Pregnancy: Teratogenic Effects: Ofloxacin has been shown to have an embryocidal effect in rats and in rabbits when given in doses of 810 mg/kg/day (equivalent to 9000 times the maximum recommended daily ophthalmic dose) and 160 mg/kg/day (equivalent to 1800 times the maximum recommended daily ophthalmic dose). These dosages resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively. …

How to store it

STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Distributed by: Armas Pharmaceuticals, Inc. Freehold, NJ 07728 USA Manufactured by: Ophtapharm AG, Riethofstrasse 1, Hettlingen, 8442, Switzerland (CHE) for Sentiss Ma …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2023-10-23.

Label for ofloxacin and ornidazole, the active ingredient registered with NAFDAC.

Check your pack of Nidof Tablet_

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC · WHO · U.S. FDA · Health Canada · NLM

About Nidof Tablet_

What is in Nidof Tablet_?

Nidof Tablet_ contains Ofloxacin; Ornidazole (200 mg; 500 mg), as tablet, according to its NAFDAC registration record.

Is Nidof Tablet_ registered with NAFDAC?

Yes. Nidof Tablet_ is listed on the NAFDAC register under registration number A4-8011, and its registration is active as of 28 October 2026.

Has Nidof Tablet_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Nidof Tablet_ in our automatically synced alert list.

How can I check that my pack of Nidof Tablet_ is genuine?

Run a free authenticity scan with the NAFDAC number A4-8011, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Nidof Tablet_?

Follow your prescription or the leaflet in your pack. The official label says: The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Days 1 and 2 Instill one to two drops every two to four hours in the affected eye(s). Days 3 through 7 Instill one to two drops four times daily. The recommended dosage regimen for the treatment of bacterial corneal ulcer is: Days 1 and 2 Instill one to two drops into the affected eye every 30 minu…

What is Nidof Tablet_ used for?

Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: (Summarised from the official U.S. FDA label for ofloxacin and ornidazole. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Nidof Tablet_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.